Opinion · 21 Feb 2022
OpinionPublished 30 Jun 2021
Hereditary profiling of CLL: a 'TP53 fiend' opinion
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Chronic Lymphocytic Leukemia (CLL) is a B-cell danger with an exceptionally factor clinical course. While a few patients require treatment moderately before long determination, others may stay liberated from side effects for a long time with a standard ‘observe furthermore, stand by’ reconnaissance approach.
Keywords
Subjects
HaematologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Hematology and Clinical Therapeutics.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Hematology and Clinical Therapeutics
- SubjectHaematology
- BylineArticles whose byline prints “Kritika Kundaliya”

